Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations.

Hersh BP, Earl NL, Hauser RA, Stacy M.

Mov Disord. 2010 May 15;25(7):927-31. doi: 10.1002/mds.23040.

PMID:
20461810
2.

Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.

Lyons KE, Friedman JH, Hermanowicz N, Isaacson SH, Hauser RA, Hersh BP, Silver DE, Tetrud JW, Elmer LW, Parashos SA, Struck LK, Lew MF, Pahwa R.

Clin Neuropharmacol. 2010 Jan-Feb;33(1):5-10. doi: 10.1097/WNF.0b013e3181b7926f.

PMID:
19855267
3.

Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study.

Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L; Ease-PD Monotherapy Study Investigators.

Curr Med Res Opin. 2008 Oct;24(10):2883-95. doi: 10.1185/03007990802387130 . Epub 2008 Sep 2.

PMID:
18768106
4.

Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.

Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, Elmer LW, Truong DD, Earl NL; EASE-PD Adjunct Study Investigators.

Neurology. 2007 Apr 3;68(14):1108-15.

PMID:
17404192
5.

Parkinsonism as the presenting manifestation of HIV infection: improvement on HAART.

Hersh BP, Rajendran PR, Battinelli D.

Neurology. 2001 Jan 23;56(2):278-9. No abstract available.

PMID:
11160977

Supplemental Content

Loading ...
Support Center